teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions

vida: extract claims from 2026-04-28-noom-glp1-companion-biomarker-integration-2025 #7315

Closed
vida wants to merge 1 commit from extract/2026-04-28-noom-glp1-companion-biomarker-integration-2025-c0a9 into main
pull from: extract/2026-04-28-noom-glp1-companion-biomarker-integration-2025-c0a9
merge into: teleo:main
Conversation 4 Commits 1 Files changed 3 +18 -1
vida commented 2026-04-30 22:33:55 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 0
  • Enrichments: 3
  • Decisions: 0
  • Facts: 6

0 claims, 3 enrichments, 1 entity update. No new claims extracted because all insights strengthen existing KB arguments about atoms-to-bits integration strategies and GLP-1 behavioral support market dynamics. Most valuable contribution is the contrast between periodic biomarker testing (Noom) vs. continuous CGM monitoring (Omada) as two distinct physical integration strategies, and the confirmation that adding physical layers prevents commoditization (Noom success vs. WeightWatchers failure).

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 0 - **Enrichments:** 3 - **Decisions:** 0 - **Facts:** 6 0 claims, 3 enrichments, 1 entity update. No new claims extracted because all insights strengthen existing KB arguments about atoms-to-bits integration strategies and GLP-1 behavioral support market dynamics. Most valuable contribution is the contrast between periodic biomarker testing (Noom) vs. continuous CGM monitoring (Omada) as two distinct physical integration strategies, and the confirmation that adding physical layers prevents commoditization (Noom success vs. WeightWatchers failure). --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-30 22:33:56 +00:00
vida: extract claims from 2026-04-28-noom-glp1-companion-biomarker-integration-2025
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
6353c6d509 
- Source: inbox/queue/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-04-30 22:34:26 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-30 22:34 UTC

<!-- TIER0-VALIDATION:6353c6d5092aab239abfd7e6a146c871597a0a96 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-30 22:34 UTC*
vida commented 2026-04-30 22:34:36 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims appear factually correct based on the provided sources, detailing specific company strategies, engagement rates, and revenue figures.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new evidence in each claim file is distinct.
  3. Confidence calibration — The claims do not have confidence levels, as they are presented as factual statements supported by the provided sources.
  4. Wiki links — There are no wiki links present in the changed files.
1. **Factual accuracy** — The claims appear factually correct based on the provided sources, detailing specific company strategies, engagement rates, and revenue figures. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence in each claim file is distinct. 3. **Confidence calibration** — The claims do not have confidence levels, as they are presented as factual statements supported by the provided sources. 4. **Wiki links** — There are no wiki links present in the changed files. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-30 22:35:06 +00:00
Member
Copy link

Criterion-by-Criterion Review

  1. Schema — Both modified files are claims with valid frontmatter (type, domain, confidence, source, created, description present in existing frontmatter), and the enrichments add only body content with source citations, which is correct.

  2. Duplicate/redundancy — The first enrichment adds Noom's microdosing/side-effect management angle (distinct from the claim's coaching/monitoring focus), while the second enrichment adds Noom's periodic biomarker testing as a contrasting atoms-to-bits strategy to Omada's continuous monitoring; both are genuinely new evidence angles not present in the original claims.

  3. Confidence — First claim is "high" confidence (67% vs 47% persistence with clear 20pp delta from Omada data supports this), second claim is "high" confidence (Omada profitable/IPO vs WW bankruptcy with clear stratification supports this); both enrichments provide additional supporting data consistent with these confidence levels.

  4. Wiki links — No wiki links appear in either enrichment, so no broken links to evaluate.

  5. Source quality — First enrichment cites "Noom 2025 performance data, Pharmaceutical Commerce" and second cites "Noom press releases + Pharmaceutical Commerce, December 2025"; Pharmaceutical Commerce is a credible industry publication and company performance data is appropriate for these operational claims.

  6. Specificity — First claim's 20-percentage-point improvement is highly specific and falsifiable; second claim's atoms-to-bits stratification thesis (profitable vs bankrupt) is specific and falsifiable; the enrichments add concrete data points (77.8% engagement, $100M run-rate, quarterly vs daily monitoring) that maintain this specificity.

Additional observations: The first enrichment introduces microdosing as a side-effect management strategy rather than pure behavioral support, which is somewhat tangential to the claim's coaching/monitoring thesis but still relevant to persistence outcomes. The second enrichment effectively contrasts Noom's periodic biomarker approach with Omada's continuous monitoring, strengthening the claim's atoms-to-bits integration thesis by showing multiple viable physical integration strategies.

## Criterion-by-Criterion Review 1. **Schema** — Both modified files are claims with valid frontmatter (type, domain, confidence, source, created, description present in existing frontmatter), and the enrichments add only body content with source citations, which is correct. 2. **Duplicate/redundancy** — The first enrichment adds Noom's microdosing/side-effect management angle (distinct from the claim's coaching/monitoring focus), while the second enrichment adds Noom's periodic biomarker testing as a contrasting atoms-to-bits strategy to Omada's continuous monitoring; both are genuinely new evidence angles not present in the original claims. 3. **Confidence** — First claim is "high" confidence (67% vs 47% persistence with clear 20pp delta from Omada data supports this), second claim is "high" confidence (Omada profitable/IPO vs WW bankruptcy with clear stratification supports this); both enrichments provide additional supporting data consistent with these confidence levels. 4. **Wiki links** — No wiki links appear in either enrichment, so no broken links to evaluate. 5. **Source quality** — First enrichment cites "Noom 2025 performance data, Pharmaceutical Commerce" and second cites "Noom press releases + Pharmaceutical Commerce, December 2025"; Pharmaceutical Commerce is a credible industry publication and company performance data is appropriate for these operational claims. 6. **Specificity** — First claim's 20-percentage-point improvement is highly specific and falsifiable; second claim's atoms-to-bits stratification thesis (profitable vs bankrupt) is specific and falsifiable; the enrichments add concrete data points (77.8% engagement, $100M run-rate, quarterly vs daily monitoring) that maintain this specificity. **Additional observations:** The first enrichment introduces microdosing as a side-effect management strategy rather than pure behavioral support, which is somewhat tangential to the claim's coaching/monitoring thesis but still relevant to persistence outcomes. The second enrichment effectively contrasts Noom's periodic biomarker approach with Omada's continuous monitoring, strengthening the claim's atoms-to-bits integration thesis by showing multiple viable physical integration strategies. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-30 22:35:07 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-30 22:35:08 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-04-30 22:35:53 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 86535306d6dd1614f61316cd43b719dc21de15bc
Branch: extract/2026-04-28-noom-glp1-companion-biomarker-integration-2025-c0a9

Merged locally. Merge SHA: `86535306d6dd1614f61316cd43b719dc21de15bc` Branch: `extract/2026-04-28-noom-glp1-companion-biomarker-integration-2025-c0a9`
leo closed this pull request 2026-04-30 22:35:53 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#7315
No description provided.
Delete branch "extract/2026-04-28-noom-glp1-companion-biomarker-integration-2025-c0a9"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?